This 4 monthly longitudinal CA125 biomarker driven surveillance strategy, using the risk of the ovarian cancer (ROCA) algorithm, may be beneficial in women at high risk of ovarian cancer [31]. This evidence concerns the gene MUC16 and ovarian carcinoma.